Thursday, October 16, 2014 10:05:24 AM
GeoVax is a clinical-stage biotechnology company developing innovative human vaccines using our novel DNA/MVA platform technology.
Our proprietary vaccine technology has been developed through multi-year collaborations with the US National Institutes of Health, the US Centers for Disease Control and Prevention, and Emory University. Our mission is to apply our expertise in areas where there is a significant unmet medical need and commercial opportunity with the goal of improving the lives of people affected by serious and life-threatening diseases.
Our primary focus is to develop vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections and we have recently expanded our research and development efforts to include vaccines to prevent Ebola virus infection.
We know our work could affect the lives of millions worldwide, and we invite you to join our effort.
http://investorshub.advfn.com/boards/board.aspx?board_id=14660
All my posts are my opinion Do your own DD before you invest. Dont invest unless you can afford to lose your entire investment.
Recent GOVX News
- GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine • GlobeNewswire Inc. • 04/04/2024 04:30:00 PM
- GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress • GlobeNewswire Inc. • 03/28/2024 01:00:00 PM
- GeoVax to Present at the 36th Annual Roth Conference • GlobeNewswire Inc. • 03/12/2024 01:00:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 03/11/2024 08:13:14 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/11/2024 04:15:24 AM
- GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System • GlobeNewswire Inc. • 03/06/2024 02:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/01/2024 09:08:47 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 09:05:14 PM
- GeoVax Reports 2023 Year-End Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:41:26 PM
- GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 • GlobeNewswire Inc. • 02/22/2024 02:00:00 PM
- GeoVax to Present at the 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/19/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:01:35 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:25 PM
- GeoVax Announces Multiple Patent Issuances and Allowances • GlobeNewswire Inc. • 02/13/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:43:48 PM
- GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster • GlobeNewswire Inc. • 02/06/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 06:13:27 PM
- GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement • GlobeNewswire Inc. • 01/29/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:03:40 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/12/2024 09:00:38 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM